Author Contributions: Dr Dasenbrook had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Dasenbrook, Checkley, Merlo, Lechtzin, Boyle.
Acquisition of data: Dasenbrook, Boyle.
Analysis and interpretation of data: Dasenbrook, Checkley, Merlo, Konstan, Lechtzin, Boyle.
Drafting of the manuscript: Dasenbrook, Boyle.
Critical revision of the manuscript for important intellectual content: Dasenbrook, Checkley, Merlo, Konstan, Lechtzin, Boyle.
Statistical analysis: Dasenbrook, Checkley, Merlo, Lechtzin.
Obtained funding: Dasenbrook, Boyle.
Administrative, technical, or material support: Dasenbrook, Konstan, Boyle.
Study supervision: Boyle.
Financial Disclosures: Dr Konstan reported serving as a consultant to Nektar, Novartis, PARI, and Transave and serving as a member of the scientific advisory board for Aradigm. Dr Lechtzin reported serving as a consultant to Transave. Dr Boyle reported serving as a consultant to Novartis, Bayer, and Gilead. No other disclosures were reported.
Funding/Support: This study was supported by grant DASENB08D0 from the Cystic Fibrosis Foundation and a Research Development Program grant to Case Western Reserve University from the Cystic Fibrosis Foundation. Dr Checkley is supported by a Clinician Scientist Award from Johns Hopkins University and a Pathway to Independence Award (K99HL096955) from the National Heart, Lung, and Blood Institute.
Role of the Sponsor: The funding organizations had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.